摘要
目的:评价内分泌联合唑来膦酸治疗晚期前列腺癌的疗效及安全性。方法:回顾分析40例晚期前列腺癌患者,给予内分泌治疗并检测血清ALP值的临床资料。结果:与基础值相比,治疗组第3、6、9、12个月血清ALP值分别减少79.3%(P=0.017)、84.7%(P=0.015)、82.9%(P=0.017)、82.5%(P=0.020);对照组分别减少45.9%(P=0.13)、35.2%(P=0.21)、30.3%(P=0.26)、20.2%(P=0.45)。治疗组血清ALP水平显著低于对照组(P<0.01)。结论:唑来膦酸可降低合并骨转移前列腺癌患者的骨代谢水平,防治肿瘤细胞及内分泌治疗引起的骨质疏松。
Objective: To evaluate the efficacy and safety of endocrine therapy combined with zoledronic acid in the treatment of advanced prostate cancer. Methods: A retrospective analysis of 40 patients with advanced prostate cancer were treated with endocrine therapy and serum ALP values. Results: Compared with baseline, after 3,6,9,12 months treatment, serum ALP values of the treatment group decreased 79.3%(P=0.017), 84.7%(P=0.015), 82.9%(P=0.017), 82.5%(P=0.020); those of the control group decreased 45.9%(P=0.13), 35.2%(P=0.21), 30.3%(P=0.26), 20.2%(P=0.45).The serum ALP level of the treatment group was significantly lower than that of the control group (P〈0.01). Conclusion: Zoledronic acid can reduce the bone metabolism of the prostate cancer patients with bone metastasis, control the induced osteoporosis caused by tumor cells and endocrine treatment.
出处
《中国当代医药》
2010年第14期36-36,39,共2页
China Modern Medicine
关键词
前列腺癌
唑来膦酸
内分泌治疗
Prostate cancer
Zoledronic acid
Endocrine therapy